Forty Seven, Inc.

Delisted

CIK 0001667633AcceleratedSmaller ReportingEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2019

Revenue

$15.68M

Net Income

$-87.62M

Total Assets

$343.59M

Equity

$317.93M

Shares Out

48.16M

Op. Cash Flow

$-78.11M

Business

Forty Seven, Inc. is a former operating company in Pharmaceutical Preparations, incorporated in Delaware. Securities are no longer actively traded on a major U.S. exchange.

Auto-generated from company profile

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31
License revenue	16	—	—	—
Research and development	84	57	37	14
General and administrative	20	15	8	5
Total operating expenses	104	72	45	20
Loss from operations	−89	−72	−45	−20
Remeasurement loss on contingent repayment obligation	−3	−331,000	—	—
Interest and other income, net	3	2	406,000	78,000
Net loss	−88	−70	−45	−20
Unrealized gains (losses) on available-for-sale securities	174,000	−38,000	−44,000	—
Comprehensive loss	−87	−70	−45	−20
Net loss per share, basic and diluted	−2.4	−3.75	−6.94	−3.15
Shares used in computing net loss per share, basic and diluted	36	19	6	6

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31
Cash and cash equivalents	214	11	24	—	—
Short-term investments	115	128	64	—	—
Prepaid expenses and other current assets	8	7	4	—	—
Total current assets	338	146	93	—	—
Property and equipment, net	1	1	1	—	—
Operating lease right-of-use assets	2	—	—	—	—
Other assets	3	2	2	—	—
Total assets	344	149	95	—	—
Accounts payable	9	5	4	—	—
Accrued liabilities	9	9	5	—	—
Lease liabilities, current	1	—	—	—	—
Deferred grant funding, current	3	2	3	—	—
Other current liabilities	859,000	—	—	—	—
Total current liabilities	23	15	11	—	—
Lease liabilities, noncurrent	844,000	—	—	—	—
Deferred rent, noncurrent	—	331,000	—	—	—
Other long-term liabilities	2	476,000	255,000	—	—
Total liabilities	26	16	12	—	—
Commitments and Contingencies (Note 6)	—	—	—	—	—
Common stock, $0.0001 par value: 200,000,000 shares authorized; 47,983,366 and 31,079,150 shares issued and outstanding at December 31, 2019 and 2018, respectively	5,000	3,000	1,000	—	—
Additional paid-in capital	545	273	4	—	—
Accumulated other comprehensive gain (loss)	92,000	−82,000	−44,000	—	—
Accumulated deficit	−227	−140	−69	—	—
Total stockholders equity	318	133	83	12	27
Total liabilities and stockholders equity	344	149	95	—	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31
Net loss	−88	−70	−45	−20
Stock-based compensation	5	3	724,000	245,000
Depreciation and amortization	523,000	401,000	371,000	134,000
Amortization of right-of-use assets	1	0	—	—
Accretion of discounts on marketable securities	−1	−744,000	0	0
Realized gain on sale of available-for-sale securities	−6,000	0	—	—
Change in fair value of contingent repayment obligation	3	331,000	0	0
Prepaid expenses and other current assets	−2	−2	−568,000	−4
Other assets	−651,000	−673,000	205,000	−2
Accounts payable	4	916,000	1	2
Accrued liabilities	−107,000	4	3	853,000
Deferred grant funding	1	−1	3	0
Lease related liabilities	−1	−123,000	−90,000	53,000
Net cash used in operating activities	−78	−66	−37	−22
Purchases of property and equipment	−356,000	−403,000	−114,000	−1
Purchases of available-for-sale securities	−166	−142	−80	−4
Proceeds from sales of available-for-sale securities	4	0	—	—
Proceeds from maturities of available-for-sale securities	176	78	16	4
Net cash provided by (used in) investing activities	14	−64	−64	−1
Proceeds from issuance of common stock upon ESPP purchase	859,000	0	—	—
Proceeds from issuance of common stock upon exercise of stock options	2	291,000	312,000	436,000
Proceeds from public offerings of common stock, net of issuance costs	264	116	—	—
Repurchase of fractional common stock upon reverse stock split	0	−1,000	0	0
Net cash provided by financing activities	267	117	115	5
Net increase (decrease) in cash and cash equivalents	203	−14	15	−18
Operating cash flows paid for operating leases	1	0	—	—
Lease liability obtained in exchange for right-of-use asset	712,000	0	—	—
Public offering costs included in accrued liabilities	264,000	0	—	—
Property and equipment purchases included in accrued liabilities	30,000	—	—	—
Conversion of convertible preferred stock to common stock at close of initial public offering	0	149	0	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro